Recro Pharma Restarting Trial For Post-Surgery Pain Drug

By

A clinical drug study by Malvern’s Recro Pharma is being refined to better differentiate the pharmaceutical, an intranasal form of dexmedetomidine called Dex-IN, from its placebo in a bid to achieve statistical significance.

Recro CEO Gerri Henwood (Courtesy of www.bizjournals.com)
Gerri Henwood (Courtesy of www.bizjournals.com)

“There remains a significant unmet medical need for opioid-sparing analgesics, a need which we continue to believe may be addressed with Dex-IN,” Recro President and CEO Gerri Henwood said in a StreetInsider.com report.

Dex-IN is being developed to treat acute pain after bunionectomy surgery, and a key change to the clinical study is administering the drug a day after surgery rather than the day of. The article noted that no serious adverse events have occurred in the trial.

Read more about the progress of Recro Pharma’s Dex-IN trial and its plan to change the study on StreetInsider.com here.
________
Top photo credit: Greg McMullin via photopin cc

Connect With Your Community

Subscribe to stay informed!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Advertisement
Creative Capital logo